

# OPTIMA HEALTH COMMUNITY CARE

## PHARMACY/MEDICAL PRIOR AUTHORIZATION REQUEST\*

**Directions:** *The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.*

**Drug Requested:**                    **Acthar® HP (Corticotropin) - INFANTILE SPASMS (IS)**

**DRUG INFORMATION:** *Complete all information below or authorization process will be delayed.*

**Drug Form/Strength/Month:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_                    **Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_                    **ICD Code, if applicable:** \_\_\_\_\_

**Note:** *(Neurology 2012;78:1974-1976) Class I study showed similar efficacy between low-dose (20-30 IU) and high dose (150 IU/m<sup>2</sup>) natural ACTH. Low dose ACTH should be considered as an alternative to high dose ACTH for treatment of infantile spasms. (Level B).*

**CLINICAL CRITERIA:** *The criteria below **must** be met to qualify or authorization process will be delayed.*

- Prescriber **MUST** be a Neurologist

**AND**

- Patient **MUST** have a documented diagnosis of Infantile Spasms

**AND**

- Approval will only be granted for a **MAXIMUM** of **30 days only** due to similar adverse effect of corticosteroids. After 2 weeks of treatment, dosing should be gradually tapered and discontinued over a 2-week period. The following is one **suggested** tapering schedule:
  - 30 U/m<sup>2</sup> in the morning for 3 days; 15 U/m<sup>2</sup> in the morning for 3 days; 10 U/m<sup>2</sup> in the morning for 3 days; and 10 U/m<sup>2</sup> every other morning for 6 days.
- Complete the regimen below (*HP Acthar gel is supplied as 5mL multidose vial containing 80 USP Units per mL*):

Approval will be a **MAXIMUM** of **30 days only** (combined inpatient and outpatient time period)

<b><u>Initial Dose Schedule</u></b>	<b><u>Approval at Outpatient pharmacy will be based on volume needed at discharge from hospital</u></b>	
75 U/m <sup>2</sup> <b>BID</b> x _____ days	TOTAL _____ mL x _____ # days (max 29 days)	
<b><u>Taper Dose Schedule</u></b>	<b><u>BODY SURFACE AREA BSA</u></b>	
30 U/m <sup>2</sup> <b>QD</b> x _____ days	_____ mL x _____ days	<b>WEIGHT:</b> _____ kg
15 U/m <sup>2</sup> <b>QD</b> x _____ days	_____ mL x _____ days	Height/Length: _____ in.
10 U/m <sup>2</sup> <b>QD</b> x _____ days	_____ mL x _____ days	Calculated BSA: _____ m <sup>2</sup>
10 U/m <sup>2</sup> <b>QOD</b> x _____ days	_____ mL x _____ days	

**TOTAL Number of vials needed:** \_\_\_\_\_/days (max 29 days)

*(signature on next page)*

**Medication being provided by a Specialty Pharmacy - PropriumRx**

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

**DEA OR NPI #:** \_\_\_\_\_

\*UPDATED/REVISED: 7/2/2018